Replies to post #3154 on Biotech Values

[DewDiligence]

>> Very dumb PR, but still a fun read: <<

That PR is about as smart as getting pulled over by a traffic cop and asking him if he plans to search the trunk.

[DewDiligence]

[UTMD] Lashing out at the FDA becoming contagious:

[First, Cyberonics; now, Utah Medical. Who will be next?]

http://biz.yahoo.com/prnews/040816/lam069_1.html

>>
UTMD's Board of Directors Comments on FDA Allegations

SALT LAKE CITY, Aug. 16 /PRNewswire-FirstCall/ -- Stephen W. Bennett, M.D., MPH&TM, Dr. PH, Barbara A. Payne, Ph.D. and Ernst G. Hoyer, B.S. Engineering, MBA, Utah Medical Products, Inc.'s (Nasdaq: UTMD - News) independent directors during the full period of time of the Company's disagreement with the Food and Drug Administration (FDA) since 2001, advise shareholders that they have been completely informed and kept current by representatives of management, independent experts and legal counsel as the Company's disagreement with the FDA has evolved.

The directors confirm their full and unanimous support for the position that, it is in UTMD shareholders' best interest to proceed through the Federal Court process because of the fundamental refusal by FDA managers to communicate.

Mr. Hoyer states

"Since the early 2002 inspection, the Company has never had an

opportunity to discuss its differences regarding inspectors'

observations with any reviewer or manager in the FDA. We have had no

opportunity to reach a reasonable resolution. As a clear example,

the Company formally requested non-binding mediation in May 2004, in

which the FDA's CDRH Ombudsman had agreed to be mediator, but were

rejected by the FDA's Tim Ulatowski.



In mediation, the FDA would be expected to say what provisions of the

QSR were in dispute and why. Instead, FDA's response was 'Tell us

what you've done to get into compliance.' I hope that the paradox is

obvious. The Company firmly believes and has believed, consistent

with the opinions of its independent experts, that it is in

compliance with the QSR."



After three years of conscientious, but futile, efforts to seek a response and dialogue with FDA management regarding the Company's numerous written responses to inspectors' observations, the only alternative FDA offered to the Company is an oppressive Consent Decree that would shut down the Company, destroy all inventory, and literally cede control to FDA personnel whose qualifications/ identity are unknown and who have refused to respond to repeated UTMD requests to meet.

Dr. Bennett, who participated in the sole meeting with agency personnel

other than inspectors after 2001, states

"There was a complete absence of good faith dialogue in the May 2003

meeting with Denver District Director Belinda Collins and Regional

Director Dennis Baker, who had requested the meeting. They were not

informed, declined to provide any information of substance, and

refused to discuss the most recently concluded inspection. The

agenda provided by UTMD could not be implemented, because information

was not exchanged. Rather, information continued to flow only in one

direction -- from UTMD to FDA.



We understand that the Company's position is unusual, and may appear

unwise to some shareholders. I assure you that we haven't been

provided another reasonable alternative.



FDA's Larry Spears, in recent public statements, has said that FDA

has identified persistent QSR violations and has given repeat

warnings to the Company. Those statements are false.



Although we would keenly prefer to be in a different situation, and

respect the mission of our FDA, the fact is that we also have the

obligation in our present extreme circumstances to stand up for the

Company's rights, employees' rights and the rights of American

citizens under explicit requirements of law and regulation, not to

mention common decency. The FDA's position is simply, 'Admit

violations (that have not been defined or discussed), and we will let

you stay in business, maybe.'



I am also very disappointed that Utah's elected representatives have

not yet taken an active interest in investigating this situation, and

in trying to keep productive law-abiding citizens in Utah employed.

We look forward to more involvement and help from Senator Bob

Bennett, Senator Orrin Hatch and Congressman Jim Matheson. I sent a

personal letter to Senator Hatch in June 2003 in which I expressed,

among other things, 'It is a sad and disturbing thing when a

government agency abuses its power particularly when both incivility

and incompetence on the part of an inspector, as in this case, is

followed by bureaucratic ineptitude and punitive actions ... I

firmly believe that a part of the FDA is out of control and behaving

contrary to its own policies, and a cover-up is in progress.'"



Dr. Payne asks

"How is this litigation by the FDA consistent with the following

August 4 campaign speech?



'John Edwards and I are campaigning across the country talking about

how we can build an America that is stronger at home and respected in

the world, and that means creating a business climate that helps

companies succeed and create good paying jobs right here in America,'

Senator Kerry said in his prepared remarks.



'Clearly, we can do a better job lowering the cost of doing business

in America. That makes us more competitive and it reduces the

incentive for somebody to decide to go overseas,' Kerry said.



How is it in the public interest to punish an innovative company

making proven safe and effective life-saving devices, ironically

because it prefers to manufacture in the U.S. and agrees with the

FDA's own December 1997 "Guide to Inspections of Medical Device

Manufacturers" which was maintained at least through UTMD's 2003

inspection? The guide, which has a section entitled "The Small

Manufacturer," states, 'An investigator should not insist that a

manufacturer meet a QS/GMP requirement that does not contribute to

its assuring conformance to specifications, simply because it's part

of the new regulation.' The guide also states, 'Section 519(a)(4) of

the FD&C (Federal Food, Drug and Cosmetic) Act prohibits record

keeping requirements that are unduly burdensome to a device

manufacturer.' The guide states, 'An investigator should realize

that a small firm usually does not need the same degree of

documentation necessary as required for a large firm to achieve a

state of control.' The guide also states, 'Practices may be more

brief and less detailed for a small manufacturer of less complicated

devices unless the firm is producing non-conforming devices.'

Despite the above consideration theoretically given small companies

by the FDA, UTMD's experts agree that the Company complies with all

provisions of the QSR.



During the multiple and burdensome FDA inspections since 2001, one

fact is certain -- UTMD devices do conform to specifications. UTMD

has many years of experience producing and shipping devices supported

by objective evidence that these meet specifications using current

manufacturing processes. The lawyers representing the government

have acknowledged that there is not a risk to public health."



The directors remind shareholders and the public that FDA statements about "violations" must be truthfully qualified. No violation exists until the FDA proves this through supporting evidence in Federal Court proceedings or the accused (UTMD) agrees to make such an admission. UTMD will not be making such an admission because, with the firm support of industry experts, it is confident in its compliance with the QSR. UTMD is proud of its continuing record of providing safe and effective devices manufactured by dedicated and qualified personnel who implement quality systems certified to compliance with the worldwide recognized ISO 13485 standard for medical devices, as further recognized by the FDA.
<<

[DewDiligence]

[CYBX] Conditional approval? Don’t tell the FDA:

http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh23876_2004-09-23_16-26-20_n23...

>>
Cyberonics gets FDA OK for small study

CHICAGO, Sept 23 (Reuters) - U.S. regulators, who rejected Cyberonics Inc.'s (CYBX.O: Quote, Profile, Research) device to treat depression in August, cleared the therapy for use in a small study, the company said on Thursday.

Cyberonics shares, down 40 percent after the U.S. Food and Drug Administration in August rejected the implantable device, rose 6.2 percent to their highest since mid-August, when the FDA rejected the company's application to use the device to treat severe depression.

But analysts noted Cyberonics, which is being pursued by Advanced Neuromodulation Systems Inc. (ANSI.O: Quote, Profile, Research) , cannot use data gathered in the study to support a regulatory submission to use the device to treat severe depression. It currently is only approved to treat epilepsy.

"From a regulatory perspective, this is essentially meaningless. However, from an experience situation, it is actually a good thing," said analyst Mark Landy of Susquehanna Financial Group.

"This is not something one can point to and say they're closer to an approval," added A.G. Edwards analyst Jan Wald, who tied Thursday's rally to short-covering.

Speculators had established large short positions, betting on a decline, when the FDA rejected the implantable device after an advisory panel recommended approval.

Cyberonics said the "conditional approval" will make the device available only to 100 patients taking part in the study. An FDA spokeswoman said there's no such thing as a conditional approval. "Either it's approved or it's not approved," she said.

A company spokesman said there seems to be "some confusion" at the FDA and said everything in the company's statement was correct.

The company sells the pacemaker-like device as a treatment for epilepsy and has been seeking approval for its use in patients with treatment-resistant depression, a population at high risk of suicide.

Houston, Texas-based Cyberonics in late August said it would try to persuade the FDA to reconsider its decision and viewed a new study as its "last-resort" option.

Analysts have largely written off the chances the FDA would reverse its decision.

"Before that product is approved for general use in the treatment of severe depression, they are going to have to do a significant randomized study as was suggested by numerous members of the advisory panel in general discussions about the application. I don't think there is any way around it. This is just a little Band-Aid," said Ira Loss, an analyst with Washington Analysis, an independent research group.

"What FDA has done here is to try to take the rough edges off a very difficult decision they had to make," he added.

Cyberonics said it continues to work through the informal appeals process as Advanced Neuromodulation urges reluctant Cyberonics' executives to enter into merger talks.

"Advanced Neuromodulation is going through the steps to work toward getting (Cyberonics) shareholders on board. Cyberonics is doing all it can to block that. There's still more to come," said William Plovanic, an analyst with First Albany Corp.

"I think part of what Cyberonics' strategy is to show in some way, shape or form that valuation is much higher. Will it turn hostile? It's already headed down that path."

Cyberonics shares were up 58 cents, or about 2.6 percent, at $23.08, in midday trading on the Nasdaq, off the day's best of $24.30.
<<